cell microarray
Allarity Therapeutics Seeks FDA Premarket Approval for Prediction Tool as CDx for Dovitinib
The DRP would be used to identify kidney cancer patients likely to benefit from dovitinib, a repurposed TKI for which Allarity plans to file an NDA this year.